FindTrial
Sign In

Understanding Key Biomarkers in Pancreatic Cancer- What Claudin 18.2, MSI, and HER2 Mean for Patients

Evaluation of Actionable Biomarkers in Pancreatic Adenocarcinoma: Clinicopathological Implications of Claudin 18.2, MSI, and HER2/neu Expression - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112850
Enrollment
100
Registered
2026-06-16
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K87- Disorders of gallbladder, biliarytract and pancreas in diseases classified elsewhere

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil Intervention4: Nil: Nil

Sponsors

tata memorial centre research administrationb council
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: It will include 1-50 cases of primary pancreatic adenocarcinoma. 2-50 cases of metastatic pancreatic adenocarcinoma. 3-Formalin-fixed paraffin-embedded (FFPE) blocks with adequate tumor cells will be selected for immunohistochemical evaluation.

Exclusion criteria

Exclusion criteria: Exclusion Criteria: 1-Precursor lesions such as pancreatic intraepithelial neoplasia (PanIN). 2-FFPE blocks with insufficient tumor tissue or poorly preserved tissue, unsuitable

Design outcomes

Primary

MeasureTime frame
To correlate the clinicopathological features of patients of pancreatic adenocarcinoma with the expressions of CLDN18.2, MMR proteins and Her2neu using immunohistochemistry.Timepoint: 18 months—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactDr Ipsita Dhal

MPMMCC

dripsitadhal@gmail.com7289004590

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026